Sanofi (SNY) Financial Statements

Executive TeamFinancials
Shareholders

Sanofi financial statements at a glance

Sanofi reported revenue of 46.72 billion EUR for fiscal year 2025 (ended December 31, 2025), up 5.5% from fiscal year 2024. Net income was 7.81 billion EUR, a net margin of 16.7%, and diluted earnings per share were 6.40 EUR.

At the end of fiscal year 2025 it had total assets of 126.81 billion EUR, total liabilities of 55.10 billion EUR and shareholders' equity of 71.38 billion EUR, with cash and short-term investments of 8.47 billion EUR and total debt of 20.33 billion EUR.

Its operations brought in 10.75 billion EUR of cash; capital spending was 3.54 billion EUR, leaving free cash flow of 7.21 billion EUR.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in EUR; latest fiscal year ended December 31, 2025.

SNY logo

Sanofi

SNYFrance
Healthcare
EUR (Local)

Income Statement

Annual • EUR

Total Revenue
46.72B
Prev Year: 44.29B
YoY: +5.5%
Operating Revenue
43.63B
Prev Year: 41.08B
YoY: +6.2%
Total Unusual Items Excluding Goodwill
-3.29B
Prev Year: -2.20B
YoY: -49.4%
Total Unusual Items
-3.29B
Prev Year: -2.20B
YoY: -49.4%
Normalized EBITDA
15.77B
Prev Year: 13.24B
YoY: +19.2%
Tax Rate for Calcs
0.169
Prev Year: 0
Tax Effect of Unusual Items
-556.21M
Prev Year: -396.72M
YoY: -40.2%
Total Operating Income as Reported
6.34B
Prev Year: 7.25B
YoY: -12.5%
Noncontrolling Interests
-38.00M
Prev Year: -58.00M
YoY: +34.5%
Equity in Earnings of Affiliates, Net of Tax
-155.00M
Prev Year: 60.00M
YoY: -358.3%
Gain on Sale of Business
485.00M
Total Other Finance Cost
-166.00M
Prev Year: 224.00M
YoY: -174.1%
Other Operating Expenses
4.21B
Prev Year: 3.29B
YoY: +27.8%
Depreciation Amortization Depletion
1.78B
Prev Year: 1.75B
YoY: +1.5%
Depreciation and amortization
1.78B
Prev Year: 1.75B
YoY: +1.5%
Amortization
1.78B
Prev Year: 1.75B
YoY: +1.5%
Amortization of Intangibles
1.78B
Prev Year: 1.75B
YoY: +1.5%
Selling and Marketing Expense
699.00M
Cost of Revenue
13.05B
Prev Year: 13.21B
YoY: -1.2%
Gross Profit
33.67B
Prev Year: 31.08B
YoY: +8.3%
Operating Expense
24.07B
Prev Year: 21.62B
YoY: +11.3%
Selling General and Administrative
10.24B
Prev Year: 9.18B
YoY: +11.5%
General and Administrative Expense
9.54B
Other General and Administrative
9.54B
Research and Development
7.84B
Prev Year: 7.39B
YoY: +6.1%
Operating Income
9.60B
Prev Year: 9.46B
YoY: +1.4%
Net Non Operating Interest Income Expense
-129.00M
Prev Year: -560.00M
YoY: +77.0%
Non-operating Interest Income
331.00M
Prev Year: 413.00M
YoY: -19.9%
Non-operating Interest Expense
626.00M
Prev Year: 749.00M
YoY: -16.4%
Other Income Expense
-3.29B
Prev Year: -2.20B
YoY: -49.4%
Gain on Sale of Securities
-40.00M
Prev Year: 6.00M
YoY: -766.7%
Special Income Charges
-3.25B
Prev Year: -2.21B
YoY: -47.2%
Restructuring and Mergers Acquisition
1.24B
Prev Year: 1.49B
YoY: -16.8%
Impairment of Capital Assets
2.24B
Prev Year: 248.00M
YoY: +803.6%
Other Special Charges
255.00M
Prev Year: 470.00M
YoY: -45.7%
Pre-tax Income
6.17B
Prev Year: 6.70B
YoY: -7.8%
Provision for Income Taxes
1.04B
Prev Year: 1.20B
YoY: -13.4%
Net Income Common Stockholders
7.81B
Prev Year: 5.56B
YoY: +40.5%
Net Income
7.81B
Prev Year: 5.56B
YoY: +40.5%
Net Income Including Non-Controlling Interests
7.85B
Prev Year: 5.62B
YoY: +39.7%
Net Income from Continuing Operations
4.98B
Prev Year: 5.55B
YoY: -10.4%
Net Income from Discontinued Operations
2.87B
Prev Year: 64.00M
YoY: +4390.6%
Diluted NI Available to Com Stockholders
7.81B
Prev Year: 5.56B
YoY: +40.5%
Basic EPS
6.4
Prev Year: 4.44
YoY: +44.1%
Diluted EPS
6.4
Prev Year: 4.43
YoY: +44.5%
Weighted Average Shares (basic)
1.22B
Prev Year: 1.25B
YoY: -2.5%
Weighted Average Shares (diluted)
1.22B
Prev Year: 1.26B
YoY: -2.8%
Total Expenses
37.12B
Prev Year: 34.82B
YoY: +6.6%
Net Income from Continuing and Discontinued Operation
7.81B
Prev Year: 5.56B
YoY: +40.5%
Normalized Income
7.68B
Prev Year: 7.30B
YoY: +5.1%
Interest Income
331.00M
Prev Year: 413.00M
YoY: -19.9%
Interest Expense
626.00M
Prev Year: 749.00M
YoY: -16.4%
Net Interest Income
-129.00M
Prev Year: -560.00M
YoY: +77.0%
EBIT
6.80B
Prev Year: 7.45B
YoY: -8.7%
EBITDA
12.48B
Prev Year: 11.03B
YoY: +13.1%
Reconciled Cost of Revenue
9.15B
Prev Year: 11.37B
YoY: -19.5%
Reconciled Depreciation
5.68B
Prev Year: 3.59B
YoY: +58.3%
Net Income from Continuing Operation Net Minority Interest
4.94B
Prev Year: 5.50B
YoY: -10.1%
Values in EUR

Sanofi key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue46.7B EUR44.3B EUR41.6B EUR40.6B EUR39.2B EUR
Gross profit33.7B EUR31.1B EUR29.0B EUR28.7B EUR26.9B EUR
Operating income9.6B EUR9.5B EUR9.2B EUR10.9B EUR9.1B EUR
Net income7.8B EUR5.6B EUR5.4B EUR8.4B EUR6.2B EUR
Diluted EPS6.40 EUR4.43 EUR4.30 EUR6.66 EUR4.95 EUR
Total assets126.8B EUR132.8B EUR126.5B EUR126.7B EUR120.2B EUR
Total liabilities55.1B EUR54.9B EUR52.1B EUR51.6B EUR51.2B EUR
Shareholders' equity71.4B EUR77.5B EUR74.0B EUR74.8B EUR68.7B EUR
Cash and short-term investments8.5B EUR7.9B EUR9.0B EUR13.4B EUR11.2B EUR
Total debt20.3B EUR17.9B EUR18.4B EUR21.2B EUR22.4B EUR
Operating cash flow10.8B EUR9.1B EUR10.3B EUR10.5B EUR10.5B EUR
Capital spending3.5B EUR3.2B EUR2.9B EUR2.1B EUR2.0B EUR
Free cash flow7.2B EUR5.9B EUR7.4B EUR8.4B EUR8.5B EUR

In EUR. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Sanofi's revenue in fiscal year 2025?

46.72 billion EUR, up 5.5% from 44.29 billion EUR in fiscal year 2024.

How much profit does Sanofi make?

Sanofi reported net income of 7.81 billion EUR for fiscal year 2025 (16.7% of revenue); operating income was 9.60 billion EUR.

How much cash and debt does Sanofi have?

At the end of fiscal year 2025: cash and short-term investments of 8.47 billion EUR and total debt of 20.33 billion EUR.

What is Sanofi's free cash flow?

7.21 billion EUR in fiscal year 2025 (operating cash flow of 10.75 billion EUR minus capital spending of 3.54 billion EUR).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube